Skip to search formSkip to main contentSkip to account menu

indium In 111 ibritumomab tiuxetan

Known as: In 111 Ibritumomab Tiuxetan, In111 ibritumomab tiuxetan, Indium In-111 Ibritumomab Tiuxetan 
A radiolabeled monoclonal antibody that is used to detect certain types of B-cell non-Hodgkin lymphoma and is being studied in the detection of other… 
National Institutes of Health

Related topics

Related topics

2 relations
IDEC-In2B8/rituximabIDEC-In2B8/rituximab/yttrium Y 90 ibritumomab tiuxetan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Monoclonal Antibodies in the Treatment of Non-Hodgkin’s Lymphoma
Antibody-based therapeutic approaches have had a significant impact in the treatment of non-Hodgkin’s lymphoma (NHL). Rituximab’s… 
Highly Cited
2011
Highly Cited
2011
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using 89Zr-ibritumomab tiuxetan and PET
PurposePositron emission tomography (PET) with 89Zr-ibritumomab tiuxetan can be used to monitor biodistribution of 90Y… 
Highly Cited
2008
Highly Cited
2008
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
PURPOSE We conducted an international, randomized, phase III trial to evaluate the efficacy and safety of consolidation with… 
Highly Cited
2007
Highly Cited
2007
Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice
We retrospectively evaluated our single-center clinical experience with 90Y-ibritumomab tiuxetan and 131I-tositumomab for therapy… 
Highly Cited
2006
Highly Cited
2006
Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma
Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin), a radiolabeled monoclonal antibody against the CD20 antigen, is indicated for… 
Highly Cited
2004
Highly Cited
2004
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
We report updated time-to-event variables of a phase III randomized study comparing yttrium 90-labeled ibritumomab with rituximab… 
Highly Cited
2002
Highly Cited
2002
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
PURPOSE Rituximab is commonly used as a single agent or in combination therapy for non-Hodgkin's lymphoma (NHL). Ibritumomab… 
Review
2002
Review
2002
Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
90Y-ibritumomab tiuxetan is a novel radioimmunotherapeutic agent recently approved for the treatment of relapsed or refractory… 
Highly Cited
2002
Highly Cited
2002
Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
PURPOSE Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin; IDEC Pharmaceutical, San Diego, CA) is an effective therapy for patients… 
Review
2001
Review
2001
The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy.
  • D. Goldenberg
  • Critical reviews in oncology/hematology
  • 2001
  • Corpus ID: 36652500
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)